Noveome Biotherapeutics
Pittsburgh, US · Delaware corporation
Biotech
Founders & leadership
PW
Patrick WelchExecutive Officer
GK
Gretchen KraemerExecutive Officer
TG
Terence GoldenDirector
JM
John McArthurDirector
WG
William GoldenExecutive Officer, Director
DW
Donald WagnerDirector
AC
A. Clarke AtwellExecutive Officer, Director
RL
Robert LangerDirector
MK
Michael KaufmanDirector
EK
Eric KellerDirector
RP
Ronald PoropatichDirector
CN
Craig NemiroffDirector
Competitors · 9
by search overlapImmunome43 shared keywords
PatSnap42 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Alterome40 shared keywordsAlterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
Diabetes Prevention Program35 shared keywords
Concord Communications29 shared keywords
Cowles_Investments_StemCentrx25 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Myome25 shared keywords
Cellanome23 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
Ziprecruiter22 shared keywords
Companies competing with Noveome Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$36.2MraisedAug 2024 · 66 investors · BiotechnologyRule 506(b)
▶$36.2MraisedAug 2024 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Michael KaufmanDirector
- Patrick WelchExecutive Officer
- Eric KellerDirector
- Ronald PoropatichDirector
- Craig NemiroffDirector
- Gretchen KraemerExecutive Officer
- Houman HemmatiDirector
- Offering amount
- $51.3M
- Amount sold
- $36.2M
- Proceeds to insiders
- $186K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$870KraisedOct 2020 · 7 investors · BiotechnologyRule 506(b)
▶$870KraisedOct 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- William GoldenExecutive Officer, Director
- Patrick WelchDirector
- Terence GoldenDirector
- Donald WagnerDirector
- Offering amount
- $15M
- Amount sold
- $870K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedApr 2019 · 39 investors · BiotechnologyRule 506(b)
▶$15MraisedApr 2019 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- John McArthurDirector
- William GoldenExecutive Officer, Director
- Terence GoldenDirector
- Patrick WelchDirector
- Donald WagnerDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedApr 2016 · 39 investors · BiotechnologyRule 506(b)
▶$2.2MraisedApr 2016 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terence GoldenDirector
- John McArthurDirector
- William GoldenExecutive Officer, Director
- Donald WagnerDirector
- A. Clarke AtwellExecutive Officer, Director
- Robert LangerDirector
- Offering amount
- $2.5M
- Amount sold
- $2.2M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase I | 2012 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $147.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.